Genprex (NASDAQ:GNPX) Stock Price Up 2.1% – Still a Buy?

Genprex (NASDAQ:GNPX)’s share price rose 2.1% during trading on Monday . The company traded as high as $0.5369 and last traded at $0.5050. Approximately 270,636 shares changed hands during trading, a decline of 29% from the average daily volume of 381,310 shares. The stock had previously closed at $0.4948.

Wall Street Analyst Weigh In

Several analysts have issued reports on GNPX shares. Weiss Ratings restated a “sell (e+)” rating on shares of Genprex in a report on Tuesday, April 21st. Wall Street Zen raised shares of Genprex from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of “Sell”.

Genprex Price Performance

The stock has a market capitalization of $5.52 million, a price-to-earnings ratio of -0.04 and a beta of -0.98. The business has a fifty day moving average of $0.77 and a 200 day moving average of $1.61.

Genprex (NASDAQ:GNPX) last posted its earnings results on Wednesday, May 13th. The company reported ($0.64) earnings per share (EPS) for the quarter.

Institutional Trading of Genprex

Hedge funds and other institutional investors have recently modified their holdings of the business. Susquehanna International Group LLP lifted its position in Genprex by 11.7% in the third quarter. Susquehanna International Group LLP now owns 340,056 shares of the company’s stock valued at $58,000 after buying an additional 35,661 shares during the last quarter. Mayflower Financial Advisors LLC acquired a new stake in shares of Genprex during the first quarter valued at about $36,000. Finally, Manchester Financial Inc. acquired a new stake in shares of Genprex during the first quarter valued at about $36,000. 14.05% of the stock is owned by institutional investors and hedge funds.

About Genprex

Genprex, Inc is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.

In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes.